Omics AI Expands Collaboration with Revvity to Build 'Auto-driving Lab'

From the left, Paek Jongmin, Manager at Revvity; Park Kyungbae, Executive Director; Carola Schmidt; Antoniette Violo; Dongmyung Shin, CEO of Omics AI; Sanha Park, Researcher at BioLab; Chanil Kim, Head of the Bio Research Team. Provided by Omics AI

원본보기 아이콘

Omics AI is accelerating the development of its next-generation "Auto-driving Lab" by further strengthening its collaboration with Revvity, a global life sciences and diagnostics solutions company.

According to the company on April 21, Revvity's key automation executives recently visited Omics AI's laboratory in Korea to review the progress of their joint project and discuss future directions for collaboration. The visit was attended by Antoniette Violo, Head of Korea and Oceania and Global Business Development Director, as well as Carola Schmidt, Global Technology Platform Lead, who joined the executives of Revvity Korea.

The two companies are currently working on a "Physical AI Auto-driving Lab" project by combining Revvity's advanced automation equipment with Omics AI's AI-based data analysis technology. This project aims to automate and intelligently streamline the entire research process, from experimental design to data generation, analysis, and interpretation. It is expected to become a next-generation research infrastructure that can significantly enhance the productivity and accuracy of the pharmaceutical and biotech industries.

In particular, this visit focused not only on discussions of collaboration, but also on establishing a mid- to long-term strategy to maximize technical synergy between the two companies and to explore equipment advancement based on data accumulated from actual operations.

Dongmyeong Shin, CEO of Omics AI, stated, "This collaboration is an important turning point that goes beyond simply supplying equipment, as it enables the realization of a fully autonomous experimental environment combining AI and automation technologies. Together with Revvity, we will set a new standard for next-generation life sciences research."

Revvity also emphasized the importance of the partnership. Antoniette Violo said, "Our collaboration with Omics AI is a key project that accelerates the future of AI-based experimental automation. We will further advance our technology by incorporating on-site feedback and deliver innovative solutions to the global market."

Meanwhile, Omics AI is striving to evolve into a global bio data infrastructure company, centering on its protein data-based AI platform and self-driving lab technology. The strengthened partnership with Revvity is expected to further solidify its technological competitiveness in the global market.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.